Article

Study: patients with poor vision incur greater medical costs

Baltimore-The impact of poor vision costs Medicare more than $2 billion each year for non-eye-care-related concerns, prompting a call by some to put further emphasis on vision health for all Americans.

Baltimore-The impact of poor vision costs Medicare more than $2 billion each year for non-eye-care-related concerns, prompting a call by some to put further emphasis on vision health for all Americans.

A study conducted by researchers affiliated with the Potomac Institute for Policy Studies, the Wilmer Eye Institute at Johns Hopkins University School of Medicine, and Pfizer Inc. found that Medicare beneficiaries with vision loss incurred significantly higher costs than those with normal vision. About 90% of those costs were non-eye-related.

The study evaluated a 5% sampling (about 1.5 million cases) of Medicare beneficiaries continuously enrolled from 1999 to 2003. Those with vision loss experienced increases in depression, injuries, and the need for nursing home facilities.

Jonathan C. Javitt, MD, MPH, lead researcher on the study, said Medicare spent $2.14 billion in 2003 on non-eye-related medical costs for those who were blind or had vision loss.

More than half of the cases were attributed to age-related macular degeneration and glaucoma.

A significant number were linked to cataracts that had not been surgically removed, Dr. Javitt added.

All of those conditions are treatable, said H. Dunbar Hoskins Jr., MD, executive vice president for the American Academy of Ophthalmology (AAO). The AAO said Medicare and insurance companies should put a stronger emphasis on providing preventive eye care for all Americans.

"With the soaring costs of health care, this study is an important reminder that preventing vision loss saves both sight and money," Dr. Hoskins said in a prepared statement.

"With this study, we are seeing the serious economic impact of poor vision health on the health-care system and those who pay for it," Dr. Javitt said in a prepared statement.

Priscilla P. Arnold, MD, FACS, who leads the American Society of Cataract and Refractive Surgery's government relations committee, deemed the study "important" and said she hopes it will focus attention on the need for better public eye care.

"Dr. Javitts' study has identified a significant gap and opportunity to address public health care," Dr. Arnold said. "Simple vision assessment by a primary-care provider will not identify either of those diseases in their early stages. The findings of this study indicate that critical opportunities to preserve vision are lost without regular ophthalmic-specific examination and care."

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.